Compare Novo Nordisk A/S (NVO) vs Oxford Lane Capital Corp (OXLC) Price & Performance

Novo Nordisk A/STrade

Oxford Lane Capital CorpTrade

Price performance (Past 24H)

Key statistics

Novo Nordisk A/S vs Oxford Lane Capital Corp — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while Oxford Lane Capital Corp trades at $8.82 (market cap $866.15M). The key difference: Novo Nordisk A/S is far larger — about 254.6× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays the higher dividend (27.06%). Which is the better fit depends on your goals.

	NVO	OXLC
Market Cap	$220.53B	$866.15M
Sector	Health	Financials
52-Week High	$71.70	$19.90
52-Week Low	$35.29	$8.15
Enterprise Value	$239.49B	—
Dividend Yield	3.63%	27.06%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $49.38, down 1.87% amid legal action against Eli Lilly over GLP-1 drug advertising. The stock maintains strong fundamentals with a P/E of 11.91 and robust profitability margins (net income margin 37.2%, ROE 71.4%). Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.04 surpassing the $0.87 estimate. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $48.

Outlook remains positive given strong earnings momentum and market leadership in GLP-1 drugs, though legal risks and competitive pressures from Eli Lilly pose near-term headwinds. Analyst consensus is bullish (57.9% buy ratings) with projected revenue growth to $327.8B in 2026. Key risks include litigation outcomes and market share competition in the weight-loss drug segment.

Oxford Lane Capital Corp

No Aura AI signal available yet.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

NVO

Novo Nordisk sues Eli Lilly over misleading GLP-1 drug ads claiming superior weight-loss results.Proactive Investors · 12 hours agoBearish Novo Nordisk sues Eli Lilly over misleading ads on obesity and diabetes drug efficacy.CNBC · 16 hours agoBearish Novo Nordisk shares jump 27% on strong sales of oral Wegovy and market expansion.Seeking Alpha · 1 day agoBullish View details →

OXLC

Oxford Lane Capital to release Q1 fiscal earnings and hold conference call on July 28, 2026GlobeNewsWire · 15 hours agoNeutral View details →

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

About Oxford Lane Capital Corp

Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.